País: Canadá
Língua: inglês
Origem: Health Canada
VALPROIC ACID
SANDOZ CANADA INCORPORATED
N03AG01
VALPROIC ACID
250MG
CAPSULE
VALPROIC ACID 250MG
ORAL
100
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0112996001; AHFS:
CANCELLED POST MARKET
2019-08-01
_ _ _ _ _Page 1 of 48 _ PRODUCT MONOGRAPH PR SANDOZ VALPROIC Valproic Acid 250 mg Capsules Mfr. Std. Antiepileptic Sandoz Canada Inc. Date of Revision: December 18, 2018 110 Rue de Lauzon Boucherville, QC, Canada J4B 1E6 Submission Control No: 222665 _ _ _ _ _Page 2 of 48 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................................ 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS ........................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 19 DRUG INTERACTIONS ......................................................................................................... 23 DOSAGE AND ADMINISTRATION ..................................................................................... 31 OVERDOSAGE ........................................................................................................................ 33 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 34 STORAGE AND STABILITY ................................................................................................. 36 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................... 36 PART II: SCIENTIFIC INFORMATION ................................................................................ 37 PHARMACEUTICAL INFORMATION ................................................................................. 37 CLINICAL TRIALS ............................................................................................................ Leia o documento completo